BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November 13.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thomas Shrader has given his Buy rating due to a combination of factors that highlight the potential of Gain Therapeutics’ innovative approach to treating diseases like Parkinson’s Disease and Gaucher’s Disease. The company’s strategy involves correcting mutant GCase and enhancing the transport of the wild-type enzyme, which is a promising method that could significantly impact disease treatment. Gain Therapeutics’ focus on identifying allosteric pockets to stabilize GCase in its active form is particularly noteworthy, as it could improve cellular health by ensuring proper enzyme function.
Furthermore, recent preclinical data presented at a major neuroscience conference demonstrated the efficacy of GT-02287 in modulating mitochondrial GCase, reducing mitochondrial stress, and enhancing neuronal survival. These findings add to the growing evidence supporting the therapeutic potential of GT-02287. With upcoming biomarker data expected soon, there is anticipation around the drug’s ability to clear aggregated substrates in lysosomes and reduce toxic alpha-synuclein levels, which could further validate the company’s approach and drive interest from potential partners.
In another report released on November 13, Roth MKM also reiterated a Buy rating on the stock with a $6.00 price target.
GANX’s price has also changed dramatically for the past six months – from $1.910 to $2.850, which is a 49.21% increase.